Drug profile · INN
plozasiran sodium
REDEMPLO
plozasiran sodium (REDEMPLO) is an FDA-listed pharmaceutical active ingredient. Associated with Arrowhead Pharmaceuticals Ireland Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — plozasiran sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 3
- Data quality
- 0.89
Quick answer
plozasiran sodium (REDEMPLO) is an FDA-listed pharmaceutical active ingredient. Associated with Arrowhead Pharmaceuticals Ireland Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted -
US 12173086
Alpha-v beta-6 integrin ligands and uses thereof
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted -
US 12065458
Trialkyne linking agents and methods of use
granted -
US 12054718
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
granted -
US 11920134
Compositions and methods for inhibiting expression of RRM2 genes
granted -
US 11845937
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
granted -
US 11840688
Compositions and methods for inhibiting gene expression of Hif2alpha
granted -
US 11597701
Integrin ligands and uses thereof
granted -
US 11590156
RNAi agents for hepatitis B virus infection
granted -
US 11517584
RNAi agents for Hepatitis B virus infection
granted -
US 11492624
RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
granted -
US 11214801
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 11214802
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
granted -
US 11208662
RNAi inhibition of alpha-ENaC expression
granted -
US 11180529
Alpha-v beta-6 integrin ligands and uses thereof
granted
Frequently asked questions
What is plozasiran sodium?
plozasiran sodium (REDEMPLO) is an FDA-listed pharmaceutical active ingredient. Associated with Arrowhead Pharmaceuticals Ireland Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for plozasiran sodium?
REDEMPLO is a marketed brand name for plozasiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of plozasiran sodium?
plozasiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.